News

To support the marketing application, the company has also provided the positive results of a Phase 3 efficacy trial which met primary endpoint and showed safety profile consistent

Specifically, the USPTO has issued claims in three patents covering LNP formulations and lipid components used in Tekmira’s LNP formulations. This includes two issued patents covering the cationic

Instem claimed that Provantis is a preclinical research technology solution that is easy to use and will offer dual language operation and protocol-driven automation that will produce quality

Turnbull has played different roles in her career including chairman of the New South Wales Government’s Ministerial Advisory Committee on Biotechnology (2001-2), a director of the Sydney Cancer

Progenics’ monoclonal antibodies constitute a non-antibiotic treatment strategy that is designed to block the harmful effects of the disease-causing toxins produced by C difficile. Progenics Pharma founder, CEO

With this transaction, InterMune and Roche have terminated the collaboration agreement that the companies had forged in October 2006. InterMune stated that it will make no further investment

Aridol is a single-use, indirect test that is easy-to-administer, requires minimal preparation time and only a 15% reduction in lung function from baseline, Pharmaxis said. Aridol is used

Ista Pharma said that the Phase 1/2 study was a double-masked, randomised, placebo-controlled, parallel-group study evaluating the safety and efficacy of three concentrations of Bepotastine besilate, dosed twice

Lysteda Phase 3 trial is a double-blind, placebo-controlled 6-month study which assessed the drug in women ages 18-49 years with HMB, defined as mean menstrual blood loss of